SA
NBIX icon

Sanctuary Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Sanctuary Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.19M Buy
18,927
+11,048
+140% +$1.64M 0.01% 791
2026
Q1 		$1.04M Sell
7,879
-571
-7% -$75.8K 0.01% 1312
2025
Q4 		$1.2M Buy
8,450
+388
+5% +$56.2K 0.01% 1226
2025
Q3 		$1.13M Buy
8,062
+1,450
+22% +$196K 0.01% 1219
2025
Q2 		$831K Buy
6,612
+2,656
+67% +$305K 0.01% 1331
2025
Q1 		$437K Sell
3,956
-4,235
-52% -$536K ﹤0.01% 1599
2024
Q4 		$1.26M Buy
8,191
+542
+7% +$67K 0.01% 1117
2024
Q3 		$961K Buy
7,649
+3,898
+104% +$534K 0.01% 1268
2024
Q2 		$510K Buy
+3,751
New +$514K ﹤0.01% 1626

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sanctuary Advisors's NBIX Position: Q2 2026 in Review

Sanctuary Advisors increased its Neurocrine Biosciences (NBIX) stake by 140% in Q2 2026, buying an estimated $1.64M and bringing the position to 18,927 shares worth $3.19M. The position accounts for 0.01% of the portfolio, ranked #791.

Sanctuary Advisors first reported a position in NBIX in Q2 2024 and has held it in 9 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Sanctuary Advisors held 18,927 shares of Neurocrine Biosciences worth $3.19M as of Q2 2026.
  • Sanctuary Advisors bought 11,048 Neurocrine Biosciences shares in Q2 2026, an estimated $1.64M.
  • Neurocrine Biosciences made up 0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #791 holding.
  • Sanctuary Advisors first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 9 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.